A major breakthrough in liver cancer in ten years! The first-line treatment of Roche Tecentriq and Avastin (Special Sanqi and Anvidin) significantly extends the total survival!

May 26, 2020 /
BiovalleyBIOON/ -- Recently, the evaluation of Roche's anti-PD-L1 therapy Tecentriq (Special, generic name: atezolizumab, Atezolizumab) united avastin (Anvetin), generic name: bevacizumab, bevamono) first-line treatment of non-rectructable hepatocellular carcinoma (HCC) Phase III IMbrave150 (NCT03434379) results published in the New England Journal of Medicine (NEJM)The articleheadline:Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaThe data showed thatthe combined drug regimen of tecentriq and Avastin was significantly more effective than the standard nursing drug sorafenibIMbrave150, an open label, multicenter, randomized Phase III study conducted in patients with non-rectructive, pre-localized or metastatic HCC who had not previously received systematic treatment, investigated the efficacy and safety of tecentriq and Avastin's combination treatment plan relative to the standard nursing drug, the polykinase inhibitor sorafenibIn the study, patients were randomly assigned at a 2:1 ratio and received tecentriq-Avastin combination therapy (n-336) or Sorafenni (n-165) until an unacceptable toxic reaction occurred or the clinical benefit was lostThe common primary endpoint of the study was total survival (OS) and non-progressive survival (PFS) determined by an independent assessment agency based on the solid tumor efficacy evaluation criteria 1.1 (RECIST 1.1)results showed that the study reached a common primary endpoint: both TECentriq-Avastin combined treatment groups, OS and PFS, showed statistical and clinical improvements compared to the Sorafeni groupspecific data are: at the main analytical point (August 29, 2019), the total lifetime of the Tecentriq-Avastin combined treatment group was significantly longer (median OS: NE vs 13.2 months), The risk of death was reduced by 42% (HR: 0.58, 95% CI: 0.42-0.79, p 0.001), and 12-month survival rate increased (67.2% vs 54.6%)In addition, compared to the Sorafeni group, the progression less progressive survival of the Tecentriq-Avastin group (median PFS: 6.8 months vs4.3 months), and a 41% reduction in the risk of disease progression or death (HR-0.59, 95% CI: 0.47-0.76, p 0.001)the study, tecentriq and Avastin combined drug safety were consistent with the known safety of each drug, and no new safety signals were foundThe incidence of a level 3 or 4 adverse event was 56.5% in the Tecentriq-Avastin combined treatment group, 55.1% in the Sorafeni group, and 15.2% of patients in the Tecentriq-Avastin combined treatment group had a level 3 or 4hypertension;liver cancer is a leading cause of death worldwide, especially in Asia, and hepatocellular carcinoma is the most common typeBased on the above results, IMbrave150 is the first phase III cancer immunotherapy study to improve OS and PFS in the most commonliver cancertherapytheTecentriq and Avastin combination synods is the first treatment to improve total survival in patients with non-resocative hepatocellular carcinoma who were previously not systematically treated in more than a decaderegulatory aspects, the U.SThe FDAis currently reviewing additional applications for the Tecentriq-Avastin portfolio through a real-timeoncologyreview pilot projectPreviously, the program had beenFDAto qualify for breakthrough drugs In China, the program was accepted by China's State Drug Administration (NMPA) in January Roche has developed an extensive development plan for Tecentriq, including a number of ongoing and planned Phase III studies involving multiple types of lung cancer, genitourinary cancer, skin cancer, breast cancer , gastrointestinal cancer, gynaecological cancer and head and neck cancer This includes studies of Tecentriq alone or in combination with other drugs Tecentriq is a PD-(L)1 tumor immunotherapy designed to bind to a protein called PD-L1 expressed on tumor cells and tumor inlatuated immune cells, blocking its interaction with PD-1 and B7.1 receptors By inhibiting PD-1, Tecentriq activates T-cells, which have the potential to be used as a basic combination therapy for cancer immunotherapy, targeted drugs, and chemotherapy for various types of cancer Avastin is an angiogenesis inhibitor that is targeted in combination with angiother growth factor (VEGF) VEGF plays an important role in the generation and maintenance of angiogenesis in the life cycle of tumors Avastin infects the tumor's blood supply by binding directly to VEGF, preventing it from interacting with receptors on blood vessel cells The blood supply of tumors is considered to be key to the ability to grow and metastasize in the body tumor the combination of Tecentriq and Avastin has strong scientific basis, and the Tecentriq-Avastin combination has the potential to strengthen the immune system to fight tumors In addition to having a given anti-angiogenic effect, Avastin can further enhance Tecentriq's ability to restore the body's anti-cancer immunity by inhibiting VEGF-related immunosuppression, promoting T-cell tumor immersion, and initiating T-cell response to tumor antigens December 2018, U.S FDA approves Tecentriq-Avastin-Avastin-plus chemotherapy (caplatinum and yew alcohol) for first-line treatment of adult patients without EGFR or ALK genomic tumor metamorphosis metastatic non-squamous non-small cell lung cancer (NSq NSCLC) The approval was based on data from group B patients in the IMpower150 study: in patients with active treatment of wild type (ITT-WT), tecentriq plus A-chemotherapy significantly extended the survival of patients compared to Avastin-A-Chemotherapy (median OS: 19.2 months vs 14.7 months, HR-0.78, p-0.016) (biovalleybioon.com) original source: Atezolizumab plus Bevacizumab in Unresectable Hepato Carcinoma
https://